300 related articles for article (PubMed ID: 19589104)
1. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.
Giovanella L; Maffioli M; Ceriani L; De Palma D; Spriano G
Clin Chem Lab Med; 2009; 47(8):1001-4. PubMed ID: 19589104
[TBL] [Abstract][Full Text] [Related]
2. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
3. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
4. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk?
Flores-Rebollar A; Pérez-Díaz I; Lagunas-Bárcenas S; García-Martínez B; Rivera-Moscoso R; Fagundo-Sierra R
Acta Otorhinolaryngol Ital; 2018 Jun; 38(3):188-193. PubMed ID: 29984794
[TBL] [Abstract][Full Text] [Related]
6. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
[TBL] [Abstract][Full Text] [Related]
7. High-sensitive 2nd generation thyroglobulin immunoradiometric assay. Clinical application in differentiated thyroid cancer management.
Giovanella L; Ceriani L; Garancini S
Q J Nucl Med; 2002 Dec; 46(4):319-22. PubMed ID: 12411872
[TBL] [Abstract][Full Text] [Related]
8. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
9. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer.
Giovanella L; Ceriani L
Clin Chem Lab Med; 2002 May; 40(5):480-4. PubMed ID: 12113292
[TBL] [Abstract][Full Text] [Related]
10. High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?
Trimboli P; La Torre D; Ceriani L; Condorelli E; Laurenti O; Romanelli F; Ventura C; Signore A; Valabrega S; Giovanella L
Horm Metab Res; 2013 Sep; 45(9):664-8. PubMed ID: 23720229
[TBL] [Abstract][Full Text] [Related]
11. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound?
Rosário PW; Borges MA; Fagundes TA; Franco AC; Purisch S
Clin Endocrinol (Oxf); 2005 Feb; 62(2):121-5. PubMed ID: 15670185
[TBL] [Abstract][Full Text] [Related]
12. Serum Thyroglobulin Measured With a Second-Generation Assay in Patients Undergoing Total Thyroidectomy Without Radioiodine Remnant Ablation: A Prospective Study.
Rosario PW; Mourão GF; Siman TL; Calsolari MR
Thyroid; 2015 Jul; 25(7):769-75. PubMed ID: 25763842
[TBL] [Abstract][Full Text] [Related]
13. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer.
Piccardo A; Arecco F; Morbelli S; Bianchi P; Barbera F; Finessi M; Corvisieri S; Pestarino E; Foppiani L; Villavecchia G; Cabria M; Orlandi F
J Endocrinol Invest; 2010 Feb; 33(2):83-7. PubMed ID: 19636213
[TBL] [Abstract][Full Text] [Related]
14. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
[TBL] [Abstract][Full Text] [Related]
15. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
[TBL] [Abstract][Full Text] [Related]
16. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels.
Castagna MG; Brilli L; Pilli T; Montanaro A; Cipri C; Fioravanti C; Sestini F; Capezzone M; Pacini F
J Clin Endocrinol Metab; 2008 Jan; 93(1):76-81. PubMed ID: 17971424
[TBL] [Abstract][Full Text] [Related]
17. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.
Frasoldati A; Pesenti M; Gallo M; Caroggio A; Salvo D; Valcavi R
Cancer; 2003 Jan; 97(1):90-6. PubMed ID: 12491509
[TBL] [Abstract][Full Text] [Related]
19. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
[TBL] [Abstract][Full Text] [Related]
20. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
